Cytek Biosciences (CTKB) Accumulated Depreciation & Amortization (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Accumulated Depreciation & Amortization data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation & Amortization fell 0.53% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (down 0.53% YoY), and the FY2025 full-year result was $7.6 million, up 5.09% from the prior year.
• Accumulated Depreciation & Amortization for Q1 2026 stood at $1.9 million, down from $7.6 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $7.6 million in Q4 2025 and bottomed at $1.0 million in Q1 2023.
• The 5-year median for Accumulated Depreciation & Amortization is $2.6 million (2023), against an average of $3.6 million.
• Peak annual rise in Accumulated Depreciation & Amortization reached 155.17% in 2023, while the deepest fall reached 54.54% in 2023.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $2.5 million in 2022, then jumped by 142.7% to $6.0 million in 2023, then increased by 19.25% to $7.2 million in 2024, then grew by 5.09% to $7.6 million in 2025, then plunged by 75.39% to $1.9 million in 2026.
• The last three Accumulated Depreciation & Amortization figures came in at $1.9 million (Q1 2026), $7.6 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.

Peer Comparison